Literature DB >> 2439221

Diagnosis and treatment of malignant pleural effusion.

F H Hausheer, J W Yarbro.   

Abstract

Pleural effusion is a common and important complication of malignancy which may at times be difficult to diagnose or treat. Its well recognized association with numerous diseases plus the limitations of our usual diagnostic tests may occasionally cause difficulty. In the oncology patient there are a number of common medical problems associated with the development of pleural effusion which frequently coexist with the malignancy. Pleural effusion may be a presenting or late sign of cancer, and when recurrent can be a vexing symptomatic problem. Fortunately, an increasing number of effective diagnostic and therapeutic modalities are available which, when judiciously applied, facilitate our approach.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439221     DOI: 10.1007/bf00047607

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  117 in total

1.  Pleural effusion; a statistical study of 436 patients.

Authors:  E C LEUALLEN; D T CARR
Journal:  N Engl J Med       Date:  1955-01-20       Impact factor: 91.245

2.  Pleural fluid pH in parapneumonic effusions.

Authors:  D E Potts; D C Levin; S A Sahn
Journal:  Chest       Date:  1976-09       Impact factor: 9.410

3.  Evaluation of talc pleural symphysis in management of malignant pleural effusion.

Authors:  A R Shedbalkar; J M Head; L R Head; D J Murphy; J H Mason
Journal:  J Thorac Cardiovasc Surg       Date:  1971-03       Impact factor: 5.209

4.  Re-expansion pulmonary edema.

Authors:  J L Ratliff; C M Chavez; A Jamchuk; J E Forestner; J H Conn
Journal:  Chest       Date:  1973-11       Impact factor: 9.410

5.  Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis.

Authors:  G R Jones
Journal:  Thorax       Date:  1969-01       Impact factor: 9.139

6.  Pulmonary blood flow to rapidly reexpanded lung in spontaneous pneumothorax.

Authors:  S Yamazaki; J Ogawa; A Shohzu; Y Suzuki
Journal:  Chest       Date:  1982-01       Impact factor: 9.410

7.  Computed tomography in mesothelioma.

Authors:  L Kreel
Journal:  Semin Oncol       Date:  1981-09       Impact factor: 4.929

8.  Influence of alterations in Starling forces on visceral pleural fluid movement.

Authors:  G T Kinasewitz; A P Fishman
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1981-09

9.  The pathogenesis of low glucose, low pH malignant effusions.

Authors:  J T Good; D A Taryle; S A Sahn
Journal:  Am Rev Respir Dis       Date:  1985-05

10.  Cytogenetic study of pleural effusions.

Authors:  C Carlevaro; G A Rossi; E Cerri; D Pelucco
Journal:  Tumori       Date:  1978-06-30
View more
  6 in total

Review 1.  Adenocarcinoma cells in effusion cytology as a diagnostic pitfall with potential impact on clinical management: a case report with brief review of immunomarkers.

Authors:  Sinchita Roy Chowdhuri; Patricia Fetsch; Jennifer Squires; Elise Kohn; Armando C Filie
Journal:  Diagn Cytopathol       Date:  2012-11-16       Impact factor: 1.582

Review 2.  Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.

Authors:  Periklis Perikleous; David A Waller
Journal:  J Vis Surg       Date:  2017-06-22

Review 3.  Surgical and other invasive approaches to recurrent pleural effusion with malignant etiology.

Authors:  Siyamek Neragi-Miandoab
Journal:  Support Care Cancer       Date:  2008-02-08       Impact factor: 3.603

4.  An update in the management of malignant pleural effusion.

Authors:  Dk Muduly; Svs Deo; Ts Subi; Aa Kallianpur; Nk Shukla
Journal:  Indian J Palliat Care       Date:  2011-05

5.  Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer.

Authors:  Nikolaos Barbetakis; Theodoros Antoniadis; Christodoulos Tsilikas
Journal:  World J Surg Oncol       Date:  2004-05-20       Impact factor: 2.754

6.  Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer.

Authors:  Nikolaos Barbetakis; Michalis Vassiliadis; Konstantinos Kaplanis; Rosalia Valeri; Christodoulos Tsilikas
Journal:  BMC Palliat Care       Date:  2004-09-09       Impact factor: 3.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.